



SumiSaujana Group Bhd

Company Update

BUY (↔)

research@mersec.com.my

Monday, June 15, 2026

Price: RM 0.095

Target Price: RM 0.138 (↔)


Growth Trajectory Sustained Amid Macro Headwinds

SumiSaujana's 1QFY26 performance indicates that underlying growth remains intact, supported by contributions from ongoing initiatives and resilient demand in key markets. While macro headwinds in the Middle East persist, these were largely mitigated by stronger performance from the US and Asia Pacific. FY26E/FY27E earnings estimates maintained. We maintain our BUY call, with unchanged TP of RM0.138 based on unchanged 17.5x P/E multiple.

We attended SumiSaujana's recent 1QFY26 post-results briefing and the key operational insights and outlook takeaways are as below:

- Pressures arise in the Middle East.** Management struck a cautiously optimistic tone on the outlook, supported by resilient demand across its key markets despite ongoing macroeconomic uncertainties. The US market continues to perform well and is expected to remain supportive into 2QFY26, while Asia Pacific demand has stayed broadly stable. In addition, the Group is seeing increasing interest from Africa, presenting a potential avenue for incremental growth. These positives have partly mitigated softer activity in the Middle East, where geopolitical tensions continue to weigh on project execution and customer spending. The hydrocarbon segment, particularly petrochemicals, remains challenging, compounded by aggressive competition from Chinese suppliers that has compressed industry ASPs by an estimated 12%-15% YoY. Nevertheless, management noted that customers are increasingly prioritising reliability and security of supply over pricing considerations. To mitigate margin pressures arising from pricing competition and Ringgit appreciation, the Group implemented average price increases of approximately 5% in 1QFY26, alongside procurement optimisation, cost immunisation measures and organisational realignment initiatives.
- Execution broadly on schedule.** The Pengerang project is now expected to commence by end-June to early July 2026, with manpower already mobilised ahead of deployment. Meanwhile, the Indonesian Wet Sulphuric Acid (WSA) initiative with Pertamina and Topsoe has progressed to the finalisation of the Heads of Agreement under the proposed BOOT framework. Although negotiations have advanced at a slower pace over the past two months due to local developments in Indonesia, management views the additional time as conducive to ensuring optimal project structuring. Separately, the CoolisT collaboration has progressed into the production trial stage following the submission of its first batch of products, with test results expected to guide the next phase of commercialisation. The Group is also in the final stages of evaluating its US manufacturing strategy, with a decision anticipated within the next one to two months.
- IPO proceeds utilization.** As at 31st March 2026, the Group has successfully deployed 90.8% of its RM74.4m IPO proceeds, with >50% allocated to the acquisition of its new Puncak Alam warehouse and corporate office, completed early May 2026 with title transfer concluded. Subsequently, the Group has consolidated warehouse operations and ceased rental of three external premises. Also recall that the Group had previously terminated their tenancy (annual rental of RM720k) for their existing Puncak Alam factory upon completion of the acquisition. Additional investments in IT infrastructure, solar PV and R&D expansion

Share Price Performance



Business Overview

SUMI Group Bhd manufacture specialty chemicals for the oil & gas industry's upstream, midstream and downstream sectors. Their products, ranging from drilling fluid and production chemicals to refinery additives. Listed in the ACE Market under Oil & Gas.

Return Information

KLCI (pts)	1,683.63
YTD KLCI chg.	0.2%
YTD Stock Price chg.	-17.4%

Price Performance

Absolute (%)	-5.0%	-13.6%	-44.1%
Relative to KLCI (%)	-1.2%	-12.7%	-55.0%

Stock Information

Market Cap (RM m)	137.1
Issued Shares (m)	1,443.6
52-week High (RM)	0.19
52-week Low (RM)	0.08
Est. Free Float (%)	31.1
Beta vs FBM KLCI	N.A
3-month Avg Vol. (m)	1,213,201
Shariah Compliant	Yes
Bloomberg Ticker	SUMI MK EQUITY

Top 3 Shareholders

	%
Atreon Holdings Bhd	65.0
Norazlam bin Norbi	1.7
Toh Chee Seng	1.7

FY Dec (RM m)	FY25A	FY26E	FY27E
Revenue	183.6	181.9	189.2
EBITDA	17.2	23.9	25.2
PBT	12.8	15.5	15.2
Net Profit	8.3	11.0	11.6
Core Net Profit	8.3	11.0	11.6
Consensus Net Profit	-	11.5	17.3
Earnings Revision (%)	-	-	-
Core EPS (sen)	0.58	0.76	0.80
Core EPS Growth (%)	-51%	32%	5%
Net DPS (sen)	-	0.23	0.24
Net Div. Yield (%)	-	2.08	2.19
BV Per Share (sen)	11.66	12.19	12.75
P/E (x)	19.0	14.4	13.7
PBV (x)	0.9	0.9	0.9
ROE (%)	5%	6%	6%



are also progressing as planned. While these initiatives have contributed to higher depreciation charges in the near term, they should enhance operating efficiency, improve cost visibility and support future expansion.

Earnings estimates. We maintain our FY26E/FY27E earnings estimates while incorporating higher production output assumptions at c.15,200 tonnes (previously c.14,400 tonnes) and revised ASP/tonne estimates at c.RM9,200 (previously c.RM9,700) following the latest briefing. Our core assumptions remain unchanged, including the absence of one-off listing expenses, a stable USD/MYR outlook and a 29% effective tax rate in line with management guidance. The revisions reflect stronger underlying demand from Asia Pacific and the US, which continue to mitigate weakness in the Middle East.

Valuation. We reiterate our **BUY** call and TP of **RM0.138**, based on an unchanged **17.5x FY27E PER**. While weakness in the Middle East and industry pricing pressures may continue to weigh on near-term sentiment, we believe these risks are adequately reflected in current valuations. Importantly, the Group continued to deliver underlying growth, as evidenced by the 11.6% YoY revenue expansion in what is typically its seasonally softer first quarter, underscoring the resilience of its diversified earnings base and structural growth trajectory. At below **1.0x FY26E/FY27E P/BV**, we believe SumiSaujana's strong balance sheet, geographic diversification and visible execution pipeline remain underappreciated by the market.

Outlook. While macro headwinds, particularly Middle Eastern weakness and industry-wide pricing pressures are likely to persist in the near term, the Group's diversified market exposure and resilient underlying demand continue to support its growth trajectory, as reflected by the 11.6% YoY revenue expansion in a seasonally softer first quarter. Concurrently, the ongoing transition towards an owner-operated model through the acquisition of its factory and warehouse assets should progressively translate into recurring cost savings, improved operational efficiency, and tighter control over logistics and inventory management. Management highlighted direct rental savings of approximately RM720k per annum from the Puncak Alam factory, alongside additional cost efficiencies from the consolidation and exit of multiple leased warehouse facilities. Looking ahead, key execution milestones include the commencement of the Pengerang contract, formalisation of the WSA framework, commercial validation of the CoolisT initiative, and clarity on the US manufacturing strategy, which collectively provide potential support to medium and long-term earnings growth.

Investment case. We remain constructive for the long-term outlook on SUMI, underpinned by its defensible market position and strategic diversification. The Group's core strength lies in its robust institutional ties, with its top four global O&G clients—led by Petronas—accounting for 78% of revenue (c.80% revenue comes from Asia-Pacific/Americas). Beyond its legacy portfolio, SUMI is pivoting toward high-growth industrial applications, specifically bio-based lubricants and transformer oils. This expansion is supported by a dual-track strategy: (i) geographical scaling, with new production facilities in North America and the Middle East slated for execution by 1HFY26, and (ii) innovation-led growth via its MPOB partnership, leveraging palm-based polyols to capture the accelerating demand for sustainable biochemicals.

Risks to our recommendation include: (i) Dependence on key customers, (ii) Foreign currency exposure, (iii) Raw materials input cost fluctuation.

This section is left blank intentionally

Disclaimer & Disclosure of Conflict of Interest

This report has been prepared by research analyst(s) of Mercury Securities pursuant to the Research Incentive Program under Bursa Research Incentive Scheme Plus (“Bursa RISE+”) administered by Bursa Malaysia Berhad. This report has been produced independent of any influence from Bursa Malaysia Berhad or the subject company. Bursa Malaysia Berhad and its group of companies disclaim any and all liability, howsoever arising, out of or in relation to the administration of Bursa Research Incentive Program and/or this report. This research report can also be found in the Bursa Marketplace or via the link: <https://www.bursamarketplace.com/mkt/tools/research>.

The information contained in this report is based on data obtained from data and sources believed to be reliable at the time of issue of this report. However, the data and/or sources have not been independently verified and as such, no representation, express or implied, are made as to the accuracy, adequacy, completeness or reliability of the information or opinions in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as “believe”, “estimate”, “intend” and “expect” and statements that an event or result “may”, “will” or “might” occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to Mercury Securities Sdn Bhd. (“Mercury Securities”) and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. Mercury Securities expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

Accordingly, neither Mercury Securities nor any of its holding company, related companies, directors, employees, agents and/or associates nor person connected to it accept any liability whatsoever for any direct, indirect, or consequential losses (including loss of profits) or damages that may arise from the use or reliance on the information or opinions in this publication. Any information, opinions or recommendations contained herein are subject to change at any time without prior notice. Mercury Securities has no obligation to update its opinion or the information in this report.

This report does not have regard to the specific investment objectives, financial situation and particular needs of any specific person. Accordingly, investors are advised to make their own independent evaluation of the information contained in this report and seek advice from, amongst others, tax, accounting, financial planner, legal or other business professionals regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise represents a personal recommendation to you. This report is not intended, and should not under no circumstances be considered as an offer to sell or a solicitation of any offer or a solicitation or expression of views to influence any one to buy or sell the securities referred to herein or any related financial instruments.

Mercury Securities and its holding company, related companies, directors, employees, agents, associates and/or person connected with it may, from time to time, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or be materially interested in any securities mentioned herein or any securities related thereto, and may further act as market maker or have assumed underwriting commitment or deal with such securities and provide advisory, investment, share margin facility or other services for or do business with any companies or entities mentioned in this report. In reviewing the report, investors should be aware that any or all of the foregoing among other things, may give rise to real or potential conflict of interests and should exercise their own judgement before making any investment decisions.

This research report is being supplied to you on a strictly confidential basis solely for your information and is made strictly on the basis that it will remain confidential. All materials presented in this report, unless specifically indicated otherwise, are under copyright to Mercury Securities. This research report and its contents may not be reproduced, stored in a retrieval system, redistributed, transmitted, or passed on, directly or indirectly, to any person or published in whole or in part, or altered in any way, for any purpose.

This report may provide the addresses of, or contain hyperlinks to websites. Mercury Securities takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to Mercury Securities own website material) are provided solely for your convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or Mercury Securities’ website shall be at your own risk.

This report is not directed to or intended for distribution or publication outside Malaysia. If you are outside Malaysia, you should have regard to the laws of the jurisdiction in which you are located.

The views expressed in this research report accurately reflect the analyst’s personal views about any and all of the subject securities or issuers; and no part of the research analyst’s compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.



Recommendation Rating

Mercury Securities maintains a list of stock coverage. Stock can be added or dropped subject to needs with or without notice. Hence, the recommendation rating only applicable to stocks under the list. Stocks out of the coverage list will not carry recommendation rating as the analyst may not follow the stocks adequately.

Mercury Securities has the following recommendation rating:

BUY	Stock's total return is expected to be +10% or better over the next 12 months (including dividend yield)
HOLD	Stock's total return is expected to be within +10% or -10% over the next 12 months (including dividend yield)
SELL	Stock's total return is expected to be -10% or worse over the next 12 months (including dividend yield)

Published & Printed By:

MERCURY SECURITIES SDN BHD
Registration No. 198401000672 (113193-W)
L-7-2, No 2, Jalan Solaris, Solaris Mont' Kiara, 50480 Kuala Lumpur
Telephone: (603) - 6203 7227
Website: www.mercurysecurities.com.my
Email: mercurykl@mersec.com.my